Brokerages Expect Xenon Pharmaceuticals Inc (XENE) Will Announce Earnings of -$0.48 Per Share

Brokerages expect Xenon Pharmaceuticals Inc (NASDAQ:XENE) to announce earnings per share (EPS) of ($0.48) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Xenon Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.49) and the highest is ($0.47). Xenon Pharmaceuticals posted earnings per share of ($0.43) in the same quarter last year, which would suggest a negative year-over-year growth rate of 11.6%. The company is scheduled to announce its next quarterly earnings report on Tuesday, May 8th.

According to Zacks, analysts expect that Xenon Pharmaceuticals will report full-year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($1.79) to ($1.21). For the next year, analysts forecast that the firm will post earnings of ($1.69) per share, with EPS estimates ranging from ($1.88) to ($1.49). Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Xenon Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.34). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $6.38 million. Xenon Pharmaceuticals had a negative return on equity of 65.72% and a negative net margin of 9,872.67%.

A number of research firms have commented on XENE. Jefferies Group raised their price target on shares of Xenon Pharmaceuticals to $6.00 and gave the stock a “buy” rating in a report on Thursday. Stifel Nicolaus raised their price objective on shares of Xenon Pharmaceuticals from $7.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, March 8th. ValuEngine raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Finally, Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $6.67.

Several institutional investors have recently added to or reduced their stakes in XENE. K2 Principal Fund L.P. lifted its stake in shares of Xenon Pharmaceuticals by 33.5% in the fourth quarter. K2 Principal Fund L.P. now owns 219,543 shares of the biopharmaceutical company’s stock valued at $620,000 after buying an additional 55,033 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Xenon Pharmaceuticals by 59.2% in the fourth quarter. Renaissance Technologies LLC now owns 249,000 shares of the biopharmaceutical company’s stock valued at $703,000 after buying an additional 92,600 shares in the last quarter. Finally, Sabby Management LLC lifted its stake in shares of Xenon Pharmaceuticals by 7.1% in the fourth quarter. Sabby Management LLC now owns 329,400 shares of the biopharmaceutical company’s stock valued at $931,000 after buying an additional 21,800 shares in the last quarter. 50.87% of the stock is currently owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals (NASDAQ XENE) traded up $0.05 during trading hours on Monday, reaching $4.80. 34,911 shares of the company’s stock were exchanged, compared to its average volume of 65,404. The company has a debt-to-equity ratio of 0.17, a current ratio of 10.98 and a quick ratio of 10.99. The firm has a market capitalization of $85.51, a PE ratio of -2.79 and a beta of 1.10. Xenon Pharmaceuticals has a 1-year low of $2.10 and a 1-year high of $5.00.

TRADEMARK VIOLATION NOTICE: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3303291/brokerages-expect-xenon-pharmaceuticals-inc-xene-will-announce-earnings-of-0-48-per-share.html.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Get a free copy of the Zacks research report on Xenon Pharmaceuticals (XENE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

WGL Holdings  Expected to Post Quarterly Sales of $848.00 Million
WGL Holdings Expected to Post Quarterly Sales of $848.00 Million
Analysts Anticipate WesBanco  to Post $0.73 Earnings Per Share
Analysts Anticipate WesBanco to Post $0.73 Earnings Per Share
Zacks: Analysts Anticipate Urstadt Biddle Properties Inc.  to Announce $0.34 EPS
Zacks: Analysts Anticipate Urstadt Biddle Properties Inc. to Announce $0.34 EPS
Blue Hills Bancorp  Announces Quarterly  Earnings Results
Blue Hills Bancorp Announces Quarterly Earnings Results
Head to Head Survey: IRIDEX  versus BioSig Technologies
Head to Head Survey: IRIDEX versus BioSig Technologies
The Children’s Place  & The Competition Head to Head Contrast
The Children’s Place & The Competition Head to Head Contrast


© 2006-2018 Ticker Report. Google+.